Neuphoria Therapeutics Inc.
NEUP evidence brief
What we can confirm
- BioSniper Score:
- 7.2 / 10
- Market Cap:
- $20.2M
- Lead Asset:
- bnc105 (Preclinical)
What it means
What to watch
Prepared research question
What matters most for NEUP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NEUP
Neuphoria Therapeutics Inc. (NEUP) is a clinical-stage biotechnology company developing treatments for neuropsychiatric disorders, with a lead candidate in Phase 3 for social anxiety disorder and a partnered Phase 2 program in Alzheimer's disease, while also pursuing a merger with Scancell Holdings plc.
Key risk: Phase 3 readout delay
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$20.2M
Cash Runway
—
Lead Asset
bnc105 (Preclinical)
Next Catalyst
—
Tracking 3 pipeline candidates for Neuphoria Therapeutics Inc..
Neuphoria Therapeutics Inc. (NEUP) is a clinical-stage biotechnology company developing treatments for neuropsychiatric disorders, with a lead candidate in Phase 3 for social anxiety disorder and a partnered Phase 2 program in Alzheimer's disease, while also pursuing a merger with Scancell Holdings plc.
- Lead candidate BNC-210 is in a Phase 3 trial (AFFIRM-1) for social anxiety disorder, with target enrollment of 332 participants achieved as of September 2025 [news · published 2025-09-04].
- Partnered with Merck & Co., Inc. on MK-1167 (bnc375), a Phase 2 α7 nAChR PAM for Alzheimer's disease; MSD funds all R&D and commercialization [pipeline].
- Cash runway extended through fiscal Q2 2027 as of September 2025 [news · published 2025-09-30].
- Received a revenue distribution payment of AUD $1.416M in May 2026 from the CTx CRC program related to the KAT6 program licensed to Pfizer [news · published 2026-05-26].
- Announced an all-share merger with Scancell Holdings plc in July 2026, with Scancell planning to list on Nasdaq [news · published 2026-10-09].
What works
- BNC-210 is a first-in-class, acute, 'as needed' treatment for social anxiety disorder, potentially differentiating from antidepressants and benzodiazepines [pipeline].
- The Merck partnership for MK-1167 provides full funding of R&D and commercialization, reducing Neuphoria's financial burden [pipeline].
- Cash runway extended through fiscal Q2 2027 provides operational stability for ongoing trials [news · published 2025-09-30].
What to weigh
- BNC-210's Phase 3 topline readout was anticipated in early Q4 2025 but no results have been publicly reported as of the latest news [news · published 2025-09-30].
- The company's pipeline beyond BNC-210 and MK-1167 is early-stage, with BNC-105 in preclinical for cancer [pipeline].
- The planned merger with Scancell introduces execution risk and potential dilution for existing shareholders [news · published 2026-10-09].
From the filings
Quoted directly from source documents.
BNC-210 Phase 3 trial achieved target enrollment of 332 participants.
“today announced the achievement of target enrollment of 332 participants in the AFFIRM-1 Phase 3 trial evaluating lead candidate BNC-210”
News · September 4, 2025
Merck funds all R&D and commercialization for MK-1167.
“MSD funds current and future research and development activities, including clinical development and worldwide commercialization.”
Cash runway extended through fiscal Q2 2027.
“Cash runway extended through fiscal Q2 2027”
News · September 30, 2025
Neuphoria received a revenue distribution payment from CTx CRC in May 2026.
“On May 21, 2026, Neuphoria Therapeutics Inc. (the "Company") received a revenue distribution payment of AUD $1.416M from its participation in the former Cancer Therapeutics Cooperative Research Centre (CTx CRC)”
News · May 26, 2026
Risks & what to watch (3)›
Key risks
- Phase 3 readout delay — Topline data for BNC-210 in SAD was expected in early Q4 2025 but no results have been reported [news · published 2025-09-30].
- Merger execution risk — The all-share merger with Scancell introduces integration and dilution risks for Neuphoria shareholders [news · published 2026-10-09].
- Early pipeline dependency — Beyond BNC-210 and MK-1167, the pipeline is early-stage (preclinical BNC-105) [pipeline].
What to watch
- Topline results from the AFFIRM-1 Phase 3 trial of BNC-210 in social anxiety disorder [news · published 2025-09-30].
- Progress of the Merck-partnered MK-1167 Phase 2 trial in Alzheimer's disease [pipeline].
- Completion of the all-share merger with Scancell and subsequent Nasdaq listing [news · published 2026-10-09].
- Potential milestone payments from the KAT6 program licensed to Pfizer [news · published 2026-05-26].
Sources: Competitor trials · News · Pipeline · Generated October 11, 2026 · How we verify sources →
Run Neuphoria Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Neuphoria Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 3
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
19
Total value held
$7.0M
| Holder | Shares | Value |
|---|---|---|
| lynx1 capital management lp | 875,328 | $3.6M |
| advisorshares investments llc | 155,367 | $632K |
| shay capital llc | 151,010 | $615K |
| balyasny asset management l.p. | 142,183 | $579K |
| vanguard capital management llc | 98,516 | $401K |
| squadron capital management llc | 76,728 | $312K |
| geode capital management, llc | 52,007 | $212K |
| ikarian capital, llc | 47,443 | $193K |
| vanguard fiduciary trust co | 33,589 | $137K |
| adar1 capital management, llc | 30,000 | $122K |
Showing top 10 of 19 institutional holders of Neuphoria Therapeutics Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 0.9%
- Days to cover
- 1.0
- Shares short
- 46,010
- Daily short volume (Oct 9, 2026)
- 18.8%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NEUP short interestGovernance
Frequently asked questions
What is the AI investment thesis for Neuphoria Therapeutics Inc.?
Neuphoria Therapeutics Inc. (NEUP) is a clinical-stage biotechnology company developing treatments for neuropsychiatric disorders, with a lead candidate in Phase 3 for social anxiety disorder and a partnered Phase 2 program in Alzheimer's disease, while also pursuing a merger with Scancell Holdings plc.
What is Neuphoria Therapeutics Inc.'s lead drug candidate?
Neuphoria Therapeutics Inc.'s most advanced tracked candidate is bnc105 (Preclinical) for cancer.
Who is the CEO of Neuphoria Therapeutics Inc.?
Dr. Spyridon Papapetropoulos M.D., Ph.D. is the chief executive officer of Neuphoria Therapeutics Inc. (NEUP).
Where is Neuphoria Therapeutics Inc. headquartered?
Neuphoria Therapeutics Inc. (NEUP) is headquartered in Burlington, MA, United States.
What therapeutic areas does Neuphoria Therapeutics Inc. focus on?
Neuphoria Therapeutics Inc. develops therapies across Oncology, Neurology, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.